0000950170-24-004264.txt : 20240112
0000950170-24-004264.hdr.sgml : 20240112
20240112163156
ACCESSION NUMBER: 0000950170-24-004264
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240103
FILED AS OF DATE: 20240112
DATE AS OF CHANGE: 20240112
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ciulla Thomas
CENTRAL INDEX KEY: 0001815426
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36483
FILM NUMBER: 24532445
MAIL ADDRESS:
STREET 1: C/O CLEARSIDE BIOMEDICAL, INC.
STREET 2: 900 NORTH POINT PARKWAY, SUITE 200
CITY: ALPHARETTA
STATE: GA
ZIP: 30005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Viridian Therapeutics, Inc.\DE
CENTRAL INDEX KEY: 0001590750
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 471187261
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1215
BUSINESS ADDRESS:
STREET 1: 221 CRESCENT STREET
STREET 2: BLDG. 17, SUITE 401
CITY: WALTHAM
STATE: MA
ZIP: 02453
BUSINESS PHONE: 617.272.4600
MAIL ADDRESS:
STREET 1: 221 CRESCENT STREET
STREET 2: BLDG. 17, SUITE 401
CITY: WALTHAM
STATE: MA
ZIP: 02453
FORMER COMPANY:
FORMER CONFORMED NAME: MIRAGEN THERAPEUTICS, INC.
DATE OF NAME CHANGE: 20170213
FORMER COMPANY:
FORMER CONFORMED NAME: MIRAGEN THERAPEUTICS, INC.
DATE OF NAME CHANGE: 20170213
FORMER COMPANY:
FORMER CONFORMED NAME: SIGNAL GENETICS, INC.
DATE OF NAME CHANGE: 20140710
3
1
ownership.xml
3
X0206
3
2024-01-03
0
0001590750
Viridian Therapeutics, Inc.\DE
VRDN
0001815426
Ciulla Thomas
C/O VIRIDIAN THERAPEUTICS, INC.
221 CRESCENT STREET, SUITE 401
WALTHAM
MA
02453
false
true
false
false
Chief Medical Officer
Common Stock
762
D
Stock Option (Right to Buy)
33.06
2033-03-01
Common Stock
250000
D
Stock Option (Right to Buy)
28.22
2033-04-25
Common Stock
50000
D
Stock Option (Right to Buy)
13.76
2033-11-10
Common Stock
270000
D
This option represents a right to purchase a total of 250,000 shares of the Issuer's common stock, 25% of which will vest on February 17, 2024, with the remaining vesting in approximately equal monthly installments through February 17, 2027, subject to the Reporting Person's continued service to the Issuer.
This option represents a right to purchase a total of 50,000 shares of the Issuer's common stock, 8,333 of which have vested, with the remaining vesting in approximately equal monthly installments through April 25, 2027, subject to the Reporting Person's continued service to the Issuer.
This option represents a right to purchase a total of 270,000 shares of the Issuer's common stock, 11,250 of which have vested, with the remaining vesting in approximately equal monthly installments through November 10, 2027, subject to the Reporting Person's continued service to the Issuer.
/s/ Thomas Ciulla
2024-01-12